How Are Orphan Drugmakers Faring in the Great Biotech Downturn?
George Budwell, The Motley Fool - Motley Fool - Thu Apr 17, 5:30PM CDT
There is little debate that we are now in the throes of a general market correction. And because health-care and biotech stocks were the best performers over the past few years, they are being hit particularly hard in this downturn. That said, we...
Biotech Stock Roundup: MannKind PDUFA Date Pushed Out, Alkermes Impresses with Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 16, 9:07AM CDT
The selloff in the biotech sector continued with overall sentiment remaining bearish.
BioMarin to Host First Quarter 2014 Financial Results Conference Call and Webcast on Thursday, May 1 at 5:00 p.m. ET
GlobeNewswire - Wed Apr 16, 7:15AM CDT
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, May 1, at 5:00 p.m. ET to discuss first quarter 2014 financial results and provide a general business update. The conference call will be accessible via the internet from the company's website.
Good News for BioMarin - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 6:05PM CDT
The FDA has extended Kuvan's marketing exclusivity period.
Analysts View on Biotech Equities -- Research on Organovo Holdings, BioMarin Pharma, Vertex Pharma, and Spectrum Pharma
PR Newswire - Tue Apr 15, 10:15AM CDT
On Monday, April 14, 2014, the NASDAQ Composite ended at 4,022.69, up 0.57%, the Dow Jones Industrial Average advanced 0.91%, to finish the day at 16,173.24, and the S&P 500 closed at 1,830.61, up 0.82%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 648.05, up 0.51%, while the same has fallen by 1.86% in the previous three months. Investor-Edge has initiated coverage on the following equities: Organovo Holdings Inc. (NYSE MKT: ONVO), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) and Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI). Free technical research on ONVO, BMRN, VRTX and SPPI can be downloaded upon signing up at:
Shares of BMRN Down 22.0% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Mon Apr 14, 11:02AM CDT
SmarTrend identified a Downtrend for BioMarin Pharmaceutical (NASDAQ:BMRN) on March 7th, 2014 at $75.70. In approximately 1 month, BioMarin Pharmaceutical has returned 21.96% as of today's recent price of $59.08.
Critical Alerts For Walt Disney, Walgreen, BioMarin Pharmaceuticals, Canadian Solar, and MannKind Released By InvestorsObserver
PR Newswire - Mon Apr 14, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for DIS, WAG, BMRN, CSIQ, and MNKD.
FDA Extends Market Exclusivity Six Months for BioMarin's Rare Disease Therapy KUVAN(R) (sapropterin dihydrochloride) Powder for Oral Solution and Tablets
GlobeNewswire - Mon Apr 14, 7:08AM CDT
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in the development and commercialization of therapies for rare genetic diseases, today announced that the Food and Drug Administration (FDA) granted KUVAN(R) (sapropterin dihydrochloride) Powder for Oral Solution and Tablets a six-month pediatric exclusivity extension. The FDA action extends KUVAN's market exclusivity to June 2015 and is based on studies submitted in response to a written request by the FDA to investigate the use of KUVAN in pediatric patients from birth to age 6. KUVAN formulated as Tablets and Powder for Oral Solution, is the first and only FDA-approved medication for PKU to reduce blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive phenylketonuria (PKU). KUVAN is to be used in conjunction with a Phe-restricted diet.
Clinical Trial Results and Initiation, Endowment, Product Launches, and Appointments - Analyst Notes on Regeneron, Questcor, Jazz, Ariad, and BioMarin
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA), and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
'Mad Money' Lightning Round: I Don't See a BioMarin Rally
at The Street - Fri Apr 11, 5:00AM CDT
Cramer likes Service Corp. over Carriage Services and Magnum Hunter Resources over Swift Energy.
Jim Cramer's 'Mad Money' Recap: Blame China, Greece for the Meltdown
at The Street - Thu Apr 10, 7:24PM CDT
While everything went right in America, everything was going wrong in the rest of the world -- and that apparently makes all the difference, Cramer says.
Downtrend Call Working As BioMarin Pharmaceutical Stock Falls 16.0% (BMRN)
Comtex SmarTrend(R) - Mon Apr 07, 9:56AM CDT
SmarTrend identified a Downtrend for BioMarin Pharmaceutical (NASDAQ:BMRN) on March 7th, 2014 at $75.70. In approximately 1 month, BioMarin Pharmaceutical has returned 16.01% as of today's recent price of $63.58.
The AACR Annual Meeting May Move These 2 Stocks
Todd Campbell, The Motley Fool - Motley Fool - Mon Apr 07, 8:43AM CDT
Markets slid into the weekend, sending the majority of stocks lower. But Myriad Genetics and Pfizer may see investor interest return after presentations at the American Association for Cancer Research meeting. Let's look at why the confab...
Look for Shares of BioMarin Pharmaceutical to Potentially Rebound after Yesterday's 3.17% Sell Off
Comtex SmarTrend(R) - Thu Apr 03, 4:37PM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $65.35 to a high of $68.08. Yesterday, the shares fell 3.2%, which took the trading range below the 3-day low of $66.08 on volume of 2.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Clinical Outsourcing Strategies Discussed at the Silicon Valley BioTalks Now Available Online
PRWeb - Mon Mar 31, 2:42AM CDT
Outsourcing experts from Onyx Pharmaceuticals, San Francisco State University (SFSU), BioMarin Pharmaceutical, and Clinovo discussed the topic 'Manage In-house and Outsourced Clinical Trials: Vendor Selection, Project Coordination, and Resource Management' at the eighth Silicon Valley BioTalks.
Biomarin Pharmaceutical (BMRN) Showing Signs Of Being A Roof Leaker
at The Street - Thu Mar 27, 10:02AM CDT
Trade-Ideas LLC identified Biomarin Pharmaceutical (BMRN) as a "roof leaker" (crossing below the 200-day simple moving average on higher than normal relative volume) candidate
Good News for Catalyst Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 5:30PM CDT
The independent DMC has recommended the continuation of Catalyst Pharma's phase III study on Firdapse.
Biotech Stocks Technical Review -- Research on BioCryst Pharma, Spectrum Pharma, BioMarin Pharma, and Vertex Pharma
PR Newswire - Wed Mar 26, 10:55AM CDT
On Tuesday, March 25, 2014, the NASDAQ Composite ended at 4,234.27, up 0.19%, the Dow Jones Industrial Average advanced 0.56% to 16,367.88, and the S&P 500 closed at 1,865.62, up 0.44%. The gains were broad based as nine out of 10 sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 671.69, up 0.83%, while the same has fallen by 1.64% in the last one month. Investor-Edge has initiated coverage on the following equities: BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), and Vertex Pharmaceuticals Inc. (NASDAQ: VRTX). Free technical research on BCRX, SPPI, BMRN, and VRTX can be downloaded upon signing up at:
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 1:17AM CDT
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews